Aclaris Therapeutics (NASDAQ:ACRS) has been assigned a $50.00 price target by analysts at Cantor Fitzgerald in a research report issued on Monday, January 8th. The brokerage presently has a “buy” rating on the biotechnology company’s stock. Cantor Fitzgerald’s price objective suggests a potential upside of 100.00% from the stock’s previous close.
A number of other equities research analysts have also issued reports on ACRS. Zacks Investment Research raised shares of Aclaris Therapeutics from a “hold” rating to a “buy” rating and set a $31.00 price objective for the company in a report on Tuesday, October 10th. ValuEngine lowered shares of Aclaris Therapeutics from a “hold” rating to a “sell” rating in a report on Tuesday, September 12th. Finally, BidaskClub raised shares of Aclaris Therapeutics from a “sell” rating to a “hold” rating in a report on Friday, December 29th. Two research analysts have rated the stock with a sell rating, one has assigned a hold rating and four have given a buy rating to the stock. Aclaris Therapeutics presently has an average rating of “Hold” and an average price target of $39.20.
Aclaris Therapeutics (NASDAQ:ACRS) traded down $0.51 during trading hours on Monday, reaching $25.00. 374,800 shares of the company’s stock were exchanged, compared to its average volume of 302,000. The firm has a market capitalization of $749.91 and a PE ratio of -11.57. Aclaris Therapeutics has a 52 week low of $21.32 and a 52 week high of $33.25.
Institutional investors and hedge funds have recently modified their holdings of the company. Citigroup Inc. lifted its position in shares of Aclaris Therapeutics by 171.8% during the second quarter. Citigroup Inc. now owns 4,313 shares of the biotechnology company’s stock worth $117,000 after purchasing an additional 2,726 shares in the last quarter. Legal & General Group Plc lifted its position in shares of Aclaris Therapeutics by 98.3% during the second quarter. Legal & General Group Plc now owns 5,254 shares of the biotechnology company’s stock worth $142,000 after purchasing an additional 2,605 shares in the last quarter. Cubist Systematic Strategies LLC acquired a new stake in shares of Aclaris Therapeutics during the third quarter worth about $142,000. Voya Investment Management LLC acquired a new stake in Aclaris Therapeutics in the second quarter valued at approximately $247,000. Finally, Trexquant Investment LP acquired a new stake in Aclaris Therapeutics in the third quarter valued at approximately $247,000. 92.02% of the stock is currently owned by institutional investors and hedge funds.
TRADEMARK VIOLATION NOTICE: This article was first posted by BBNS and is the property of of BBNS. If you are accessing this article on another site, it was illegally copied and reposted in violation of United States and international copyright legislation. The legal version of this article can be read at https://baseballnewssource.com/markets/aclaris-therapeutics-acrs-given-a-50-00-price-target-by-cantor-fitzgerald-analysts/1817733.html.
Aclaris Therapeutics Company Profile
Aclaris Therapeutics, Inc is a dermatologist-led, biopharmaceutical company. The Company is focused on identifying, developing and commercializing differentiated drugs for the treatment of dermatological indications. The Company is also focused on the discovery and development of kinase inhibitors to treat inflammatory and immunological disorders and cancer.
Receive News & Ratings for Aclaris Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Aclaris Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.